4DMedical Limited (ASX:4DX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 2.41B |
| Revenue (ttm) | 5.81M |
| Net Income (ttm) | -172.93M |
| Shares Out | 572.20M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,329,520 |
| Average Volume | 5,392,358 |
| Open | 4.200 |
| Previous Close | 4.220 |
| Day's Range | 4.070 - 4.440 |
| 52-Week Range | 0.225 - 5.420 |
| Beta | 2.78 |
| RSI | 60.79 |
| Earnings Date | Feb 27, 2026 |
About 4DMedical
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non‑invasive respiratory imaging solution using four‑dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of poten... [Read more]
Financial Performance
In fiscal year 2025, 4DMedical's revenue was 5.85 million, an increase of 55.91% compared to the previous year's 3.75 million. Losses were -30.07 million, -16.42% less than in 2024.
Financial StatementsNews
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health,...
4DMedical Limited (FDMDF) Discusses Imaging Technology Portfolio and Market Positioning in Cardio-Pulmonary Diagnostics Transcript
4DMedical Limited (FDMDF) Discusses Imaging Technology Portfolio and Market Positioning in Cardio-Pulmonary Diagnostics Transcript
4DMedical Limited (FDMDF) Discusses Expansion of Distribution Agreement for CT:VQ Non-Contrast Lung Imaging Solution Transcript
4DMedical Limited (FDMDF) Discusses Expansion of Distribution Agreement for CT:VQ Non-Contrast Lung Imaging Solution Transcript
4DMedical Limited - Special Call
4DMedical Limited - Special Call Company Participants Andreas Fouras - Founder, MD, CEO & Director Conference Call Participants Thomas Godfrey - Ord Minnett Limited, Research Division Kyle Hogarth Pre...
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
Medicare confirms reimbursement, unlocking nationwide access to non-contrast ventilation–perfusion imaging from routine chest CT LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- 4DMedical, a leader in adva...
4DMedical Limited - Special Call
4DMedical Limited - Special Call Company Participants Andreas Fouras - Founder, MD, CEO & Director Presentation Andreas Fouras Founder, MD, CEO & Director Hi, everyone. Thank you so much for joining u...